Adial Pharmaceuticals, Inc - Common Stock
As of June 11, 2026, Adial Pharmaceuticals, Inc. was acquired by Azora Therapeutics, Inc. Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
No fundamental data is currently available for this listing from our data providers.
No recent news available for this listing.